BrightKaire Featured in Inc.: Bringing Precision Medicine to Depression Treatment
Inc. magazine spotlights NeuroKaire's BrightKaire blood test, which uses patient-derived neurons and AI to guide antidepressant selection-ending the trial-and-error cycle for the more than 20 million adults in the U.S. living with depression.
For the more than 20 million adults in the U.S. who experience depression each year, finding the right antidepressant has long meant months of trial and error. Inc. magazine takes a closer look at how NeuroKaire is changing that.
In this feature, Inc. explores BrightKaire, our first-of-its-kind blood test that generates patient-specific neurons and uses AI to predict how an individual's brain will respond to different antidepressants—before a single pill is prescribed. The result: a faster, biology-driven path to effective treatment that gives both clinicians and patients the clarity they've long been waiting for.
Being recognized by Inc. reflects the growing momentum behind precision psychiatry—and the urgency of getting better tools into the hands of providers who treat depression every day.
Contact Us
78 John Miller Way,
Kearny, NJ 07032, USA
Yigal Alon Street 126
Tel Aviv-Yafo, Israel